Quick Answer
BiomX Inc. reported Research And Development Expense of $21.29 million for the year ending 2025.
- BiomX Inc. showed a decrease of -13.7% in Research And Development Expense from 2024 to 2025.
- This data is from BiomX Inc.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $2.74 million | Q2 2019: $2.86 million | Q3 2019: $2.86 million | Q1 2020: $3.53 million | Q2 2020: $3.72 million | Q3 2020: $6.06 million | Q1 2021: $5.67 million | Q2 2021: $3.82 million | Q3 2021: $6.61 million | Q1 2022: $4.93 million | Q2 2022: $4.58 million | Q3 2022: $3.54 million | Q1 2023: $4.56 million | Q2 2023: $3.82 million | Q3 2023: $5.64 million | Q1 2024: $4.11 million | Q2 2024: $6.90 million | Q3 2024: $7.28 million | Q1 2025: $5.25 million | Q2 2025: $5.01 million | Q3 2025: $6.12 million.
- Over the full 8 years of available data (2018 to 2025), BiomX Inc.'s Research And Development Expense has grown by 133.1%.
- Historical annual values: Fiscal year 2025: $21.29 million | Fiscal year 2024: $24.66 million | Fiscal year 2023: $16.70 million | Fiscal year 2022: $16.24 million | Fiscal year 2021: $22.68 million | Fiscal year 2020: $19.42 million | Fiscal year 2019: $13.49 million | Fiscal year 2018: $9.14 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: